Methotrexate update 2014: 70 years in autoimmunity and cancer treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F14%3A%230000563" target="_blank" >RIV/00209805:_____/14:#0000563 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/14:00087495 RIV/00159816:_____/14:00065375

Výsledek na webu

<a href="http://www.prolekare.cz/cesko-slovenska-pediatrie-clanek/70-let-methotrexatu-v-lecbe-autoimunitnich-a-nadorovych-onemocneni-49621" target="_blank" >http://www.prolekare.cz/cesko-slovenska-pediatrie-clanek/70-let-methotrexatu-v-lecbe-autoimunitnich-a-nadorovych-onemocneni-49621</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Methotrexate update 2014: 70 years in autoimmunity and cancer treatment

Popis výsledku v původním jazyce

Immunosupressive and antineoplastic activity brought methotrexate to its clinical use many years ago. Although modern antitumour and antiinflammatory drugs and new antifolates have challenged methotrexate, its use in rheumatoid arthritis and in some types of pediatric and adult malignancies remains a gold standard. The principal main mechanism of action of methotrexate is competitive inhibition of dihydrofolate reductase. Recently, other pharmacodynamic effects have been described. Potent inflammation inducers such as leukotriene-B4 and polyamine synthesis were found to be reduced by methotrexate treatment. Jun N-terminal kinase and B cell lymphoma 2 gene are downregulated by methotrexate. Its metabolite, 7-hydroxymethotrexate and also its intracellular polyglutamated forms show a different spectrum of inhibitory activity as well as potency towards dihydrofolate reductase and other enzymes. In this review, we summarize recent information data on methotrexate in both fields of its use,

Název v anglickém jazyce

Methotrexate update 2014: 70 years in autoimmunity and cancer treatment

Popis výsledku anglicky

Immunosupressive and antineoplastic activity brought methotrexate to its clinical use many years ago. Although modern antitumour and antiinflammatory drugs and new antifolates have challenged methotrexate, its use in rheumatoid arthritis and in some types of pediatric and adult malignancies remains a gold standard. The principal main mechanism of action of methotrexate is competitive inhibition of dihydrofolate reductase. Recently, other pharmacodynamic effects have been described. Potent inflammation inducers such as leukotriene-B4 and polyamine synthesis were found to be reduced by methotrexate treatment. Jun N-terminal kinase and B cell lymphoma 2 gene are downregulated by methotrexate. Its metabolite, 7-hydroxymethotrexate and also its intracellular polyglutamated forms show a different spectrum of inhibitory activity as well as potency towards dihydrofolate reductase and other enzymes. In this review, we summarize recent information data on methotrexate in both fields of its use,

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česko-Slovenská pediatrie

ISSN

0069-2328

e-ISSN

—

Svazek periodika

69

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

161-167

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—